3404Impact of anti-coagulation therapy on in-hospital outcomes of CRT patient treated with transvenous lead extraction

count, LDL-cholesterol, peak troponin T, and NT-proBNP), patients with high ds-DNA levels still had a significantly increased risk of death ], p=0.001). No significant association to clinical outcome was observed for MPO-DNA. DsDNA and MPO-DNA were both correlated with peak troponin T (r=0.17 and 0.12, respectively, p<0.001 for both), whereas only dsDNA correlated significantly with levels of p<0.001). Amongst patients with reduced left ventricular ejection fraction 40% (n=145), dsDNA and MPO-DNA levels were significantly elevated (439 ng/ml (397, 494) vs. 409 ng/ml (366, 464) and 0.196 OD (0.148, 0.312) vs. 0.175 OD (0.137, 0.254), respectively, p0.007 for both). Conclusions: In this cohort of patients with STEMI, dsDNA and MPO-DNA levels did not associate with adverse clinical outcome as defined by the primary composite endpoint. Levels of dsDNA were, however, significantly associated with increased mortality. The underlying mechanism for the apparent link between extracellular nuclear material and death is unclear and in need of further exploration.